Poland· PL-100400660
Tookad
A padeliporfin product containing padeliporfinum, registered in Poland by Steba Biotech S.A.. The same ATC class is registered in 8 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Padeliporfin is registered in 8 of 19 countries.
Countries holding a registration under ATC L01XD07 (padeliporfin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 5 of them publish a price we can compare per daily dose
Padeliporfin · ATC L01XD07
8 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Padeliporfinum
- Manufacturer
- Steba Biotech S.A.
- Country
- Poland (PL)
- ATC code
- L01XD07
- ATC class
- Padeliporfin
- Defined daily dose
- 0.26 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Padeliporfin in 7 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTookad 366 mgSteba Biotech
- CzechiaTOOKADSteba Biotech S.A., Luxembourg
- SpainTOOKAD 366 MG POLVO PARA SOLUCION INYECTABLESteba Biotech S.A.
- IcelandTookadSTEBA Biotech S.A.
- SwedenTOOKAD 200 mg Pulver till injektionsvätska, lösningSteba Biotech
- FinlandTOOKADSteba Biotech S.A.
- IrelandTOOKAD 183 mg powder for solution for injectionSTEBA Biotech S.A.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Tookad
- Liechtenstein · Tookad
- Norway · Tookad
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/db98295c-b592-4a2d-9529-f07971a5c8f9 GET /v1/drugs/db98295c-b592-4a2d-9529-f07971a5c8f9?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania roztworu do wstrzykiwań",
"source": "urpl",
"strength": "366 mg",
"packaging": "Rpz ¦ EU/1/17/1228/002 ¦ 126563\n1 fiol.",
"substance": "Padeliporfinum 366 mg",
"common_name": "Padeliporfinum",
"pl_product_id": "100400660",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about padeliporfin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.